Yuan, Y., Fang, X., Li, D., Weng, S., Hu, H., Dong, C., Xiao, Q., Wang, D., Liao, X., Wang, J., Sun, L., Xu, D., Song, Y., Li, J., Yan, S., Zhou, B., Li, G., Zhang, S., Ding, K. (2026). Tislelizumab combined with standard therapy for conversion treatment in patients with MSS, initially unresectable colorectal cancer liver metastases (CRLM): A prospective, phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.tps159